Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Arriagada, B. Bergman, A. Dunant, T. Chevalier, J. Pignon, J. Vansteenkiste (2004)
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.The New England journal of medicine, 350 4
A. Depierre, B. Milleron, D. Moro-Sibilot, S. Chevret, E. Quoix, B. Lebeau, D. Braun, J. Breton, E. Lemarié, S. Gouva, N. Paillot, J. Bréchot, H. Janicot, F. Lebas, P. Terrioux, J. Clavier, P. Foucher, M. Monchâtre, D. Coëtmeur, M. Level, P. Leclerc, F. Blanchon, J. Rodier, L. Thiberville, A. Villeneuve, V. Westeel, C. Chastang (2002)
Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 1
D. Betticher, S. Schmitz, M. Tötsch, E. Hansen, C. Joss, C. Briel, R. Schmid, M. Pless, J. Habicht, A. Roth, A. Spiliopoulos, R. Stahel, W. Weder, R. Stupp, F. Egli, M. Furrer, H. Honegger, M. Wernli, T. Cerny, H. Ris, Bern Research (2006)
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II studyBritish Journal of Cancer, 94
Douillard (2005)
ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I–III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up (Abstract 7013)J Clin Oncol, 23
D. Parkin, F. Bray, J. Ferlay, P. Pisani (2005)
Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 55
Bernward Passlick, B. Kubuschok, J. Izbicki, O. Thetter, K. Pantel (1999)
Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer.The Annals of thoracic surgery, 68 6
(2003)
Original article DOI: 10.1093/annonc/mdh099
J. Douillard, R. Rosell, M. Delena, A. Legroumellec, A. Torres, F. Carpagnano (2005)
ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist AssociationJournal of Clinical Oncology, 23
K. Pantel, J. Izbicki, M. Angstwurm, S. Braun, Bernward Passlick, O. Karg, O. Thetter, G. Riethmüller (1993)
Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer.Cancer research, 53 5
A. Calvert, D. Newell, L. Gumbrell, S. O'Reilly, M. Burnell, F. Boxall, Z. Siddik, I. Judson, M. Gore, E. Wiltshaw (1989)
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 7 11
J. Roth, E. Atkinson, F. Fossella, Ritsuko Komaki, M. Ryan, J. Putnam, Jin Lee, H. Dhingra, L. Caro, M. Chasen, W. Hong (1998)
Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.Lung cancer, 21 1
A. Jemal, R. Siegel, Elizabeth Ward, Taylor Murray, Jiaquan Xu, Carol Smigal, M. Thun (2006)
Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 56
C. Manegold, B. Bergman, A. Chemaissani, W. Dornoff, P. Drings, P. Kellokumpu-Lehtinen, K. Liippo, K. Mattson, J. Pawel, S. Ricci, C. Sederholm, R. Stahel, G. Wagenius, N. Walree, W. Bokkel-Huinink (1997)
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 8 6
C. Mountain (1997)
Revisions in the International System for Staging Lung Cancer.Chest, 111 6
N. Martini, M. Kris, B. Flehinger, R. Gralla, M. Bains, M. Burt, R. Heelan, P. McCormack, K. Pisters, J. Rigas, V. Rusch, R. Ginsberg (1993)
Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients.The Annals of thoracic surgery, 55 6
J. Schiller, D. Harrington, C. Belani, C. Langer, A. Sandler, J. Krook, Junming Zhu, David Johnson (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.The New England journal of medicine, 346 2
H. Pass, H. Pogrebniak, S. Steinberg, J. Mulshine, J. Minna (1992)
Randomized trial of neoadjuvant therapy for lung cancer: interim analysis.The Annals of thoracic surgery, 53 6
Trodella (2004)
Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA–IIIB) non-small-cell lung cancer: long-term results according to downstagingAnn Oncol, 15
I. Smith, H. Groen, J. Meerbeeck, D. Gilligan, P. Goldstraw, C. Manegold, M. Nicolson, C. Chung, A. Hodson, R. Stephens (2005)
The impact of giving neo-adjuvant chemotherapy for patients with non-small cell lung cancer (NSCLC) : data from the MRC LU22/NVALT/EORTC 08012 randomised clinical trialEjc Supplements, 3
Jocelyne Martin, R. Ginsberg, E. Venkatraman, M. Bains, R. Downey, R. Korst, M. Kris, V. Rusch (2002)
Long-term results of combined-modality therapy in resectable non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 8
W. Plunkett, Peng Huang, V. Gandhi (1995)
Preclinical characteristics of gemcitabineAnti-Cancer Drugs, 6
J. Treat, C. Belani, M. Edelman, M. Socinski, R. Ansari, C. Obasaju, J. Bloss, D. Marinucci, R. Catalano, R. Comis (2005)
A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1–99002L)Journal of Clinical Oncology, 23
D. Betticher, S. Schmitz, M. Tötsch, E. Hansen, C. Joss, C. Briel, R. Schmid, M. Pless, J. Habicht, A. Roth, A. Spiliopoulos, R. Stahel, W. Weder, R. Stupp, F. Egli, M. Furrer, H. Honegger, M. Wernli, T. Cerny, H. Ris (2003)
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 9
K. Pisters, M. Kris, R. Gralla, Muhammed Zaman, R. Heelan, Nael Martini (1993)
Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 9
N. Dubrawsky (1989)
Cancer statisticsCA: A Cancer Journal for Clinicians, 39
F. Shepherd (1993)
Screening, diagnosis, and staging of lung cancerCurrent Opinion in Oncology, 5
J. Walling (1994)
Chemotherapy for advanced non-small-cell lung cancer.Respiratory medicine, 88 9
J. D’Cunha, Angela Corfits, J. Herndon, J. Kern, L. Kohman, G. Patterson, R. Kratzke, M. Maddaus (2002)
Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761.The Journal of thoracic and cardiovascular surgery, 123 3
N. Zojwalla, H. Raftopoulos, R. Gralla (2004)
Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14_suppl
S. Ahrendt, Stephen Yang, Li Wu, Carmen Roig, P. Russell, W. Westra, J. Jen, M. Brock, R. Heitmiller, D. Sidransky (2002)
Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: preliminary results of a prospective study.The Journal of thoracic and cardiovascular surgery, 123 3
G. Scagliotti, R. Fossati, V. Torri, L. Crinò, G. Giaccone, G. Silvano, M. Martelli, M. Clerici, F. Cognetti, M. Tonato (2003)
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.Journal of the National Cancer Institute, 95 19
N. Zandwijk, E. Smit, G. Kramer, F. Schramel, Steven Gans, J. Festen, A. Termeer, N. Schlosser, C. Debruyne, Desmond Curran, G. Giaccone (2000)
Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 14
J. Treat, C. Belani, Joan Schiller, M. Monberg, J. Cunneen, Ruqin Chen, Z. Ye, C. Obasaju (2006)
Gemcitabine (G) plus carboplatin (C) at AUC 5 demonstrates reduced grade 4 thrombocytopenia rate compared to AUC 5.5 in first line therapy of patients with advanced stage NSCLC.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata, M. Tanimoto (2004)
Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 19
K. Pisters, E. Vallières, P. Bunn, J. Crowley, R. Ginsberg, P. Ellis, B. Meyers, R. Marks, J. Treat, D. Gandara (2005)
S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary resultsJournal of Clinical Oncology, 23
N. Ramnath, E. Sommers, L. Robinson, C. Nwogu, Anupama Sharma, A. Cantor, G. Bepler (2005)
Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer.Chest, 128 5
Strauss (2006)
Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633 (Abstract 7007)J Clin Oncol, 24
R. Rosell, J. Gomez-Codina, Carlos Camps, J. Sánchez, J. Maestre, José Padilla, Antonio Canto, Albert Abad, Jordi Roig (1999)
Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial.Lung cancer, 26 1
C. Mountain, C. Dresler (1997)
Regional lymph node classification for lung cancer staging.Chest, 111 6
A. Ardizzoni, M. Tiseo, L. Boni, R. Rosell, F. Fossella, J. Schiller, M. Paesmans, D. Radosavljević, A. Paccagnella, P. Mazzanti, D. Bisset (2006)
CISCA (cisplatin vs. carboplatin) meta-analysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
S. Takeda, H. Maeda, T. Okada, Toshihiko Yamaguchi, M. Nakagawa, S. Yokota, N. Sawabata, M. Ohta (2006)
Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 30 1
E. Felip, R. Rosell, B. Massutí, G. Alonso, J. González-Larriba, C. Camps, D. Isla, C. Mas, J. Sánchez, J. Maestre (2007)
The NATCH trial: Observations on the neoadjuvant armJournal of Clinical Oncology, 25
J. Schiller (2001)
Current Standards of Care in Small-Cell and Non-Small-Cell Lung CancerOncology, 61
G. Scagliotti, F. Marinis, M. Rinaldi, L. Crinò, C. Gridelli, S. Ricci, E. Matano, C. Boni, M. Marangolo, G. Failla, G. Altavilla, V. Adamo, A. Ceribelli, M. Clerici, F. Costanzo, L. Frontini, M. Tonato (2002)
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 21
K. Pisters, R. Ginsberg, D. Giroux, J. Putnam, M. Kris, David Johnson, J. Roberts, J. Mault, John Crowley, P. Bunn (2000)
Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team.The Journal of thoracic and cardiovascular surgery, 119 3
U. Gatzemeier, F. Shepherd, T. Chevalier, P. Weynants, B. Cottier, H.J.M. Groen, R. Rosso, K. Mattson, H. Cortés-Funes, M. Tonato, R. Burkes, M. Gottfried, M. Voi (1996)
Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study.European journal of cancer, 32A 2
Gary Strauss, J. Herndon, M. Maddaus, David Johnstone, Elizabeth Johnson, D. Watson, D. Sugarbaker, R. Schilsky, E. Vokes, Michael Green (2006)
Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
Marcel Rens, J. Bosch, A. Rivière, H. Elbers (2000)
Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA.Chest, 117 2
ORIGINAL ARTICLE Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer Frank C. Detterbeck, MD, FACS, FCCP,* Mark A. Socinski, MD,† Richard J. Gralla, MD,‡ Martin J. Edelman, MD,§ Thierry M. Jahan, MD, David M. Loesch, MD,¶ Steven A. Limentani, MD,# Ramaswamy Govindan, MD,** M. B. Zaman, MD,†† Zhishen Ye, PhD,‡‡ Matthew J. Monberg, MS,‡‡ and Coleman K. Obasaju, MD, PhD‡‡ survival for all patients was 45 months (65.5% censored), with Background: Surgical resection alone remains suboptimal for pa- 87.2% alive at 1 year and 69.8% alive at 2 years. tients with early-stage (I or II) non-small cell lung cancer. Two Discussion: Neoadjuvant chemotherapy with gemcitabine was fea- similar randomized phase II trials were conducted to define an active sible and well tolerated, and outcomes were similar to other reports preoperative regimen in this disease state. of this treatment strategy. However, no regimen achieved the pre- Methods: In the first study, patients were randomized to receive defined pCR rate that would be sufficient to warrant further evalu- 2 2 gemcitabine 1000 mg/m on days 1 and 8 plus cisplatin 80 mg/m on ation in the phase III setting. This trial design provides an efficient day
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Jan 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.